Hub : Traits :

Birth weight of first child

177 significantly associated models · 58 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 752566 1916587 1 1 1.3e-07 3.3e-06 5.6e-01 98 SCNN1D
2 1 11181327 12600396 1 2 3.9e-10 2.4e-11 8.8e-02 94 CLCN6
3 2 8934921 10394558 1 1 1.7e-08 1.5e-07 3.7e-01 97 ADAM17
4 2 10886098 12295638 1 1 4.8e-08 7.0e-08 1.0e+00 100 E2F6
5 3 122306920 123860565 2 1 1.4e-12 1.8e-11 2.7e-01 97 ADCY5
6 3 140350567 141867638 1 1 6.0e-08 1.1e-07 1.0e+00 100 ZBTB38
7 3 155070465 156966235 3 1 1.3e-21 3.5e-22 3.9e-02 95 KCNAB1
8 4 17104059 18507692 1 1 3.9e-08 4.2e-08 2.9e-02 84 DCAF16
9 4 105598022 107092169 1 1 1.6e-12 2.8e-16 4.1e-08 55 PPA2
10 4 145203531 146706624 1 1 1.1e-09 2.5e-10 1.4e-02 85 ANAPC10
11 6 34528785 36158878 5 3 4.3e-13 1.1e-12 5.5e-02 93 C6orf126 TEAD3 ZNF76
12 8 22687572 24125172 1 1 1.0e-07 4.5e-07 6.7e-02 87 SLC25A37
13 8 140969818 142706843 1 1 3.8e-09 8.9e-06 5.5e-01 98 PTK2
14 10 70696908 71273696 2 1 2.2e-08 1.3e-10 7.4e-04 72 SUPV3L1
15 10 95379543 96818402 1 3 2.2e-15 3.9e-14 1.0e+00 100 NOC3L
16 10 103905779 105647095 4 1 5.7e-08 9.1e-08 1.0e+00 100 NT5C2
17 11 101228512 102802722 3 1 3.0e-11 8.7e-12 1.0e+00 100 RP11-864G5.3
18 12 30084002 31526510 1 1 4.2e-10 2.4e-08 7.3e-01 100 IPO8
19 15 74488424 76108550 2 1 8.0e-08 8.7e-07 6.7e-01 99 MPI
20 15 85227407 86990983 2 1 3.3e-09 1.3e-12 7.8e-05 69 RP11-158M2.3
21 15 90718541 92135418 2 2 2.3e-15 7.7e-13 9.6e-02 95 FES
22 17 16718225 18194248 1 1 8.7e-08 2.6e-11 1.0e-06 46 PEMT
23 17 79298590 80694826 1 1 1.1e-08 6.9e-08 2.5e-01 95 DCXR
24 20 30984239 31508152 1 1 2.3e-07 1.1e-05 1.7e-04 27 C20orf203

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 2.84 2 2 4.4 0.00 1.0e+00 FES NT5C2
Depressed Affect (Nagel 2018) 1.29 1 0 0.0 0.00 1.0e+00 PTK2
Intelligence (Savage-Jansen 2018) 1.92 3 2 4.4 0.00 1.0e+00 DCAF16 PPA2 PTK2
Neuroticism (Nagel 2018) 1.10 1 0 0.0 0.00 1.0e+00 NT5C2
Schizophrenia (2018) 2.80 2 2 4.4 0.00 1.0e+00 FES NT5C2
Schizophrenia vs Biploar Disorder 1.29 1 0 0.0 0.00 1.0e+00 PTK2
Worry (Nagel 2018) 0.94 1 1 2.2 0.00 1.0e+00 NT5C2
Crohns Disease (2017) 1.59 1 1 2.2 0.00 1.0e+00 ZBTB38
Irritable Bowel Disease (IBD) 1.92 2 0 0.0 0.00 1.0e+00 IPO8 TEAD3
Ulcerative Colitis (UC) 2.10 3 0 0.0 0.00 1.0e+00 IPO8 PPA2 TEAD3
Major Depression (MDD) 2.19 1 0 0.0 0.00 1.0e+00 FES
Verbal and Numeric Reasoning (VNR) 2.07 2 2 4.4 0.00 1.0e+00 DCAF16 PPA2
Breast Cancer 1.95 3 1 2.2 0.21 7.9e-01 FES MPI ZBTB38
Prostate Cancer 2.18 1 0 0.0 0.00 1.0e+00 ZBTB38
Coronary Artery Disease (CAD) 3.01 2 0 0.0 0.00 1.0e+00 NT5C2 PEMT
Crohns Disease (2012) 1.41 1 0 0.0 0.00 1.0e+00 ZBTB38
LDL Cholesterol 1.31 1 0 0.0 0.00 1.0e+00 MPI
Lupus 1.94 2 0 0.0 0.00 1.0e+00 MPI ZNF76
Schizophrenia (2014) 2.66 2 2 4.4 0.00 1.0e+00 FES NT5C2
Blood Eosinophil Count 1.38 6 2 4.4 -0.55 2.6e-01 ADCY5 C20orf203 C6orf126 RP11-158M2.3 TEAD3 ZNF76
Blood Platelet Count 1.04 9 3 6.7 -0.08 8.2e-01 ADCY5 CLCN6 DCAF16 MPI NT5C2 RP11-158M2.3 RP11-864G5.3 SLC25A37 SUPV3L1
Blood Red Count 2.23 8 4 8.9 0.28 4.3e-01 C20orf203 CLCN6 DCXR FES MPI RP11-158M2.3 TEAD3 ZBTB38
Blood White Count 1.54 8 4 8.9 -0.50 1.7e-01 DCAF16 FES NT5C2 PPA2 PTK2 RP11-864G5.3 SUPV3L1 ZNF76
Heel T-Score 1.54 5 5 11.1 -0.45 4.5e-01 ANAPC10 DCAF16 DCXR ZBTB38 ZNF76
BMI 1.35 5 3 6.7 0.66 2.2e-01 CLCN6 DCAF16 MPI NT5C2 SLC25A37
Height 9.55 15 13 28.9 0.59 9.8e-03 ADAM17 ADCY5 ANAPC10 C6orf126 DCAF16 DCXR FES IPO8 NOC3L NT5C2 PPA2 RP11-864G5.3 TEAD3 ZBTB38 ZNF76
Waist Hip Ratio (WHR) 2.85 10 3 6.7 -0.60 6.9e-02 ADAM17 ANAPC10 C6orf126 DCXR IPO8 MPI NOC3L PEMT PTK2 ZBTB38
Systolic Blood Pressure 10.13 9 6 13.3 -0.73 1.1e-02 CLCN6 DCAF16 FES MPI NOC3L NT5C2 RP11-158M2.3 SCNN1D SLC25A37
Smoking Status 2.48 3 1 2.2 0.99 1.3e-02 FES NT5C2 PTK2
Allergy or Eczema 2.52 4 1 2.2 -0.23 7.1e-01 CLCN6 FES MPI ZBTB38
Cardiovascular Disease 6.74 6 4 8.9 -0.65 7.8e-02 CLCN6 DCAF16 FES MPI NOC3L ZNF76
Hypothyroidism (self reported) 1.53 3 1 2.2 0.00 1.0e+00 PTK2 SCNN1D SLC25A37
Respiratory disease 1.85 2 1 2.2 0.00 1.0e+00 FES ZNF76
Lung FEV1/FVC ratio 2.41 6 2 4.4 0.53 2.2e-01 ADAM17 C20orf203 NOC3L PPA2 ZBTB38 ZNF76
Lung FVC 2.98 10 8 17.8 0.61 6.2e-02 ANAPC10 C6orf126 DCAF16 DCXR IPO8 PPA2 SUPV3L1 TEAD3 ZBTB38 ZNF76
Neuroticism 1.06 1 0 0.0 0.00 1.0e+00 NT5C2
Hair Pigment 1.04 6 4 8.9 0.75 5.5e-02 C20orf203 DCXR FES PEMT ZBTB38 ZNF76
Tanning 0.40 4 1 2.2 0.51 4.9e-01 C20orf203 MPI NT5C2 TEAD3
Hand grip strength (left) 2.79 5 2 4.4 0.92 2.6e-02 DCAF16 FES NT5C2 ZBTB38 ZNF76
Number of treatments/medications taken 1.92 2 0 0.0 0.00 1.0e+00 DCAF16 FES
Sensitivity / hurt feelings 1.97 1 1 2.2 0.00 1.0e+00 FES
Hearing difficulty/problems: Yes 1.60 1 1 2.2 0.00 1.0e+00 PTK2
Relative age of first facial hair 0.96 1 0 0.0 0.00 1.0e+00 ZBTB38
Other serious medical condition/disability diagnosed by doctor 1.38 1 0 0.0 0.00 1.0e+00 PPA2
Systolic blood pressure, automated reading 8.29 7 6 13.3 -0.93 2.5e-04 CLCN6 DCAF16 FES MPI NT5C2 PPA2 SCNN1D
Angina 2.76 1 1 2.2 0.00 1.0e+00 FES
Impedance of leg (right) 1.54 5 2 4.4 -0.64 1.7e-01 FES IPO8 NT5C2 PPA2 PTK2
Leg fat-free mass (left) 5.44 11 5 11.1 0.75 8.1e-03 ANAPC10 DCAF16 FES IPO8 NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Trunk fat percentage 2.11 8 2 4.4 -0.35 3.9e-01 ADCY5 C6orf126 CLCN6 DCXR MPI SLC25A37 TEAD3 ZBTB38
Hand grip strength (right) 2.31 4 2 4.4 0.97 3.0e-02 DCAF16 NT5C2 ZBTB38 ZNF76
Current tobacco smoking 1.89 1 0 0.0 0.00 1.0e+00 NT5C2
Average weekly fortified wine intake 1.28 1 0 0.0 0.00 1.0e+00 C20orf203
Maternal smoking around birth 1.33 1 0 0.0 0.00 1.0e+00 NT5C2
Age when periods started (menarche) 1.30 1 0 0.0 0.00 1.0e+00 PEMT
High blood pressure 7.43 6 3 6.7 -0.88 4.2e-03 CLCN6 DCAF16 FES MPI PTK2 TEAD3
Hayfever, allergic rhinitis or eczema 2.19 2 1 2.2 0.00 1.0e+00 MPI ZBTB38
Stomach or abdominal pain in last month 0.95 1 0 0.0 0.00 1.0e+00 PPA2
Medication: Atenolol 3.93 1 1 2.2 0.00 1.0e+00 FES
Medication: Levothyroxine sodium 1.29 1 0 0.0 0.00 1.0e+00 SCNN1D
Sitting height 8.58 11 7 15.6 0.66 1.4e-02 ADCY5 ANAPC10 DCAF16 DCXR FES NOC3L NT5C2 PPA2 TEAD3 ZBTB38 ZNF76
Chronic bronchitis/emphysema (father) 1.58 1 0 0.0 0.00 1.0e+00 PTK2
High blood pressure (mother) 6.17 3 1 2.2 -0.60 2.9e-01 CLCN6 FES MPI
Body mass index (BMI) 1.31 5 0 0.0 0.58 3.0e-01 CLCN6 DCAF16 MPI NT5C2 SLC25A37
Impedance of leg (left) 1.56 4 2 4.4 -0.58 3.1e-01 FES NT5C2 PPA2 PTK2
Leg predicted mass (left) 5.45 11 5 11.1 0.75 8.0e-03 ANAPC10 DCAF16 FES IPO8 NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Trunk fat mass 2.66 8 3 6.7 0.50 2.1e-01 ADCY5 ANAPC10 CLCN6 DCXR MPI NT5C2 SLC25A37 ZBTB38
Waist circumference 1.85 6 2 4.4 0.55 2.6e-01 ADCY5 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Number of incorrect matches in round 1.50 2 0 0.0 0.00 1.0e+00 FES NT5C2
Past tobacco smoking 2.04 1 1 2.2 0.00 1.0e+00 NT5C2
Alcohol usually taken with meals 1.93 1 0 0.0 0.00 1.0e+00 FES
Nervous feelings 1.24 1 1 2.2 0.00 1.0e+00 NT5C2
Hearing difficulty/problems with background noise 1.53 1 0 0.0 0.00 1.0e+00 MPI
Had other major operations 1.87 1 0 0.0 0.00 1.0e+00 PPA2
Forced vital capacity (FVC) 7.07 9 8 17.8 0.97 1.6e-05 ANAPC10 C6orf126 DCAF16 DCXR IPO8 PPA2 TEAD3 ZBTB38 ZNF76
Heel bone mineral density (BMD) T-score, automated (right) 1.07 2 0 0.0 0.00 1.0e+00 DCAF16 ZBTB38
Qualifications: None of the above 1.85 2 0 0.0 0.00 1.0e+00 PPA2 PTK2
Financial difficulties in last 2 years 1.26 1 0 0.0 0.00 1.0e+00 MPI
Mouth/teeth dental problems 1.45 1 0 0.0 0.00 1.0e+00 PTK2
Heart attack 2.60 1 1 2.2 0.00 1.0e+00 FES
Allergy 2.09 4 1 2.2 -0.29 6.4e-01 CLCN6 FES ZBTB38 ZNF76
Medication: Ramipril 2.41 2 0 0.0 0.00 1.0e+00 FES MPI
Medication: Simvastatin 2.64 1 1 2.2 0.00 1.0e+00 FES
Fluid intelligence score 2.47 2 2 4.4 0.00 1.0e+00 DCAF16 PPA2
Illnesses of siblings 3.02 2 1 2.2 0.00 1.0e+00 CLCN6 FES
Weight 4.09 9 6 13.3 0.66 5.2e-02 ADCY5 ANAPC10 CLCN6 DCAF16 MPI NT5C2 PPA2 SLC25A37 ZBTB38
Impedance of arm (right) 0.95 1 0 0.0 0.00 1.0e+00 RP11-864G5.3
Arm fat percentage (right) 1.82 6 2 4.4 -0.35 5.0e-01 CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Trunk fat-free mass 7.15 11 7 15.6 0.78 4.8e-03 ADAM17 ANAPC10 C6orf126 DCAF16 NOC3L NT5C2 PPA2 PTK2 TEAD3 ZBTB38 ZNF76
Hip circumference 3.47 8 5 11.1 0.67 4.7e-02 ADCY5 ANAPC10 CLCN6 DCXR NT5C2 PEMT SLC25A37 ZBTB38
Father's age at death 3.34 2 1 2.2 0.00 1.0e+00 FES NOC3L
Worrier / anxious feelings 1.17 1 1 2.2 0.00 1.0e+00 NT5C2
Frequency of tiredness / lethargy in last 2 weeks 1.23 1 0 0.0 0.00 1.0e+00 MPI
Forced expiratory volume in 1-second (FEV1) 7.24 10 8 17.8 0.96 1.1e-06 ANAPC10 C6orf126 DCAF16 DCXR IPO8 NOC3L PPA2 TEAD3 ZBTB38 ZNF76
Pulse rate 1.94 2 1 2.2 0.00 1.0e+00 RP11-864G5.3 ZBTB38
Qualifications: A levels/AS levels or equivalent 1.40 1 0 0.0 0.00 1.0e+00 PPA2
Mouth/teeth dental problems: Dentures 1.67 1 0 0.0 0.00 1.0e+00 KCNAB1
Asthma 2.28 2 1 2.2 0.00 1.0e+00 ZBTB38 ZNF76
Medication: Cholesterol lowering 3.37 2 1 2.2 0.00 1.0e+00 CLCN6 FES
Illnesses of mother 3.71 1 1 2.2 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), Best measure 7.61 10 9 20.0 0.96 9.8e-07 ANAPC10 C6orf126 DCAF16 DCXR IPO8 NOC3L PPA2 TEAD3 ZBTB38 ZNF76
Pulse wave Arterial Stiffness index 2.71 2 0 0.0 0.00 1.0e+00 FES NT5C2
Impedance of arm (left) 0.91 2 0 0.0 0.00 1.0e+00 RP11-864G5.3 TEAD3
Arm fat mass (right) 1.91 6 1 2.2 0.92 1.0e-02 ANAPC10 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Trunk predicted mass 7.15 11 7 15.6 0.78 4.9e-03 ADAM17 ANAPC10 C6orf126 DCAF16 NOC3L NT5C2 PPA2 PTK2 TEAD3 ZBTB38 ZNF76
Standing height 9.33 12 11 24.4 0.72 3.8e-03 ADAM17 ADCY5 ANAPC10 C6orf126 DCAF16 IPO8 NOC3L NT5C2 PPA2 TEAD3 ZBTB38 ZNF76
Breastfed as a baby 2.20 2 0 0.0 0.00 1.0e+00 FES SCNN1D
Hair/balding pattern: Pattern 4 1.81 2 1 2.2 0.00 1.0e+00 FES ZBTB38
Peak expiratory flow (PEF) 3.82 7 3 6.7 0.76 4.9e-02 ANAPC10 DCAF16 MPI NT5C2 PPA2 SCNN1D ZNF76
Mouth/teeth dental problems: Bleeding gums 1.91 1 0 0.0 0.00 1.0e+00 PPA2
Medication: Paracetamol 2.12 1 1 2.2 0.00 1.0e+00 PTK2
Headache pain in last month 1.59 2 0 0.0 0.00 1.0e+00 FES IPO8
Medication for cholesterol, blood pressure or diabetes 5.56 3 2 4.4 0.72 1.7e-01 CLCN6 FES MPI
Hypothyroidism/myxoedema (self-reported) 1.35 2 0 0.0 0.00 1.0e+00 PTK2 SCNN1D
Medication: Amlodipine 3.45 2 1 2.2 -1.00 2.6e-03 CLCN6 FES
Birth weight 9.70 15 9 20.0 0.98 1.5e-10 ADAM17 ADCY5 ANAPC10 C6orf126 DCAF16 FES NT5C2 PPA2 PTK2 RP11-158M2.3 RP11-864G5.3 SLC25A37 SUPV3L1 TEAD3 ZNF76
High blood pressure (siblings) 4.15 2 2 4.4 -0.29 7.1e-01 CLCN6 FES
Forced vital capacity (FVC), Best measure 7.13 10 8 17.8 0.97 1.3e-06 ANAPC10 C6orf126 DCAF16 DCXR IPO8 NOC3L PPA2 TEAD3 ZBTB38 ZNF76
Body fat percentage 1.98 8 1 2.2 -0.35 3.9e-01 C6orf126 CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZBTB38 ZNF76
Leg fat percentage (right) 1.99 6 1 2.2 -0.31 5.5e-01 CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Arm fat-free mass (right) 5.96 11 7 15.6 0.63 3.9e-02 ADAM17 ADCY5 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Exposure to tobacco smoke outside home 1.06 1 0 0.0 0.00 1.0e+00 NT5C2
Comparative body size at age 10 1.09 1 1 2.2 0.00 1.0e+00 SUPV3L1
Worry too long after embarrassment 1.23 1 0 0.0 0.00 1.0e+00 PPA2
Age at first live birth 1.34 2 0 0.0 0.00 1.0e+00 DCAF16 PTK2
Pulse wave peak to peak time 2.41 2 0 0.0 0.00 1.0e+00 FES NT5C2
Qualifications: College or University degree 2.11 5 3 6.7 0.65 2.3e-01 DCAF16 PPA2 PTK2 RP11-864G5.3 ZBTB38
Medication for pain relief, constipation, heartburn 1.84 1 0 0.0 0.00 1.0e+00 PTK2
Neck or shoulder pain in last month 1.38 1 0 0.0 0.00 1.0e+00 PTK2
Medication: Blood pressure 6.39 3 2 4.4 -0.73 1.6e-01 CLCN6 FES MPI
Angina (self-reported) 2.81 1 1 2.2 0.00 1.0e+00 FES
Mean time to correctly identify matches 1.19 1 0 0.0 0.00 1.0e+00 FES
Whole body fat mass 2.25 7 1 2.2 0.53 2.2e-01 ADCY5 ANAPC10 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Leg fat mass (right) 1.98 6 1 2.2 0.57 2.4e-01 ADCY5 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Arm predicted mass (right) 5.96 11 7 15.6 0.63 3.9e-02 ADAM17 ADCY5 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Pulse rate, automated reading 2.18 4 2 4.4 0.94 6.5e-02 DCXR E2F6 RP11-864G5.3 ZBTB38
Alcohol intake frequency. 1.32 1 0 0.0 0.00 1.0e+00 PPA2
Comparative height size at age 10 6.88 11 6 13.3 0.79 3.7e-03 ADAM17 ANAPC10 C6orf126 DCAF16 FES NT5C2 PPA2 SUPV3L1 TEAD3 ZBTB38 ZNF76
Suffer from 'nerves' 1.33 1 0 0.0 0.00 1.0e+00 NT5C2
Medication: Aspirin 2.53 1 1 2.2 0.00 1.0e+00 FES
Knee pain experienced in last month 2.30 1 0 0.0 0.00 1.0e+00 PTK2
Hypertension (Self-reported) 7.49 6 3 6.7 -0.68 6.6e-02 CLCN6 DCAF16 FES MPI PTK2 SLC25A37
Illnesses of father: Heart disease 4.36 1 1 2.2 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), predicted 7.05 7 4 8.9 0.97 2.2e-04 ANAPC10 DCAF16 NT5C2 PPA2 TEAD3 ZBTB38 ZNF76
Whole body fat-free mass 6.54 11 7 15.6 0.87 4.4e-04 ADAM17 ANAPC10 DCAF16 IPO8 NOC3L NT5C2 PPA2 SLC25A37 TEAD3 ZBTB38 ZNF76
Leg fat-free mass (right) 5.51 11 5 11.1 0.75 8.1e-03 ANAPC10 DCAF16 FES IPO8 NOC3L NT5C2 PPA2 PTK2 SLC25A37 ZBTB38 ZNF76
Arm fat percentage (left) 1.77 6 2 4.4 -0.37 4.8e-01 CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Average weekly red wine intake 1.21 1 0 0.0 0.00 1.0e+00 MPI
Handedness (chirality/laterality): Left-handed 1.55 1 0 0.0 0.00 1.0e+00 FES
Mood swings 1.55 1 1 2.2 0.00 1.0e+00 PTK2
Qualifications: nursing, teaching 1.23 1 0 0.0 0.00 1.0e+00 PPA2
Medication for cholesterol 2.19 2 0 0.0 0.00 1.0e+00 CLCN6 FES
Back pain experienced in last month 2.34 1 0 0.0 0.00 1.0e+00 PTK2
Asthma (self-reported) 2.34 2 1 2.2 0.00 1.0e+00 ZBTB38 ZNF76
Osteoarthritis (self-reported) 1.78 2 0 0.0 0.00 1.0e+00 MPI PTK2
Medication: Aspirin 2.68 1 1 2.2 0.00 1.0e+00 FES
Illnesses of father: None of the above (group 1) 3.65 1 1 2.2 0.00 1.0e+00 FES
Smoking status: Current 1.95 1 1 2.2 0.00 1.0e+00 NT5C2
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.81 4 2 4.4 0.97 2.6e-02 ANAPC10 PPA2 TEAD3 ZNF76
Whole body water mass 6.48 12 7 15.6 0.77 3.2e-03 ADAM17 ANAPC10 DCAF16 IPO8 NOC3L NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Leg predicted mass (right) 5.53 12 5 11.1 0.75 4.6e-03 ANAPC10 DCAF16 FES IPO8 NOC3L NT5C2 PPA2 PTK2 SLC25A37 TEAD3 ZBTB38 ZNF76
Arm fat mass (left) 1.86 5 1 2.2 0.93 2.2e-02 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Number of self-reported non-cancer illnesses 2.22 2 0 0.0 0.00 1.0e+00 CLCN6 ZNF76
Average weekly champagne plus white wine intake 1.98 2 0 0.0 0.00 1.0e+00 DCXR RP11-864G5.3
Medication: Blood pressure 4.86 3 3 6.7 -0.80 1.0e-01 CLCN6 FES MPI
High cholesterol (Self-reported) 2.17 2 0 0.0 0.00 1.0e+00 CLCN6 DCAF16
Medication: Bendroflumethiazide 3.16 3 1 2.2 -0.95 5.1e-02 CLCN6 FES MPI
Medication: Paracetamol 1.99 1 0 0.0 0.00 1.0e+00 PTK2
Illnesses of father: High blood pressure 4.86 1 1 2.2 0.00 1.0e+00 FES
Ever smoked 2.16 3 1 2.2 0.00 1.0e+00 FES NT5C2 PPA2
Basal metabolic rate 5.99 12 6 13.3 0.65 2.2e-02 ADAM17 ADCY5 ANAPC10 DCAF16 IPO8 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Leg fat percentage (left) 2.11 6 1 2.2 -0.32 5.4e-01 CLCN6 DCAF16 MPI SLC25A37 TEAD3 ZNF76
Arm fat-free mass (left) 5.87 10 6 13.3 0.73 1.6e-02 ADAM17 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76
Number of operations (self-reported) 2.68 2 1 2.2 0.00 1.0e+00 PPA2 SCNN1D
Risk taking 2.04 1 0 0.0 0.00 1.0e+00 FES
Ever had prostate specific antigen (PSA) test 1.44 1 0 0.0 0.00 1.0e+00 ZBTB38
Diastolic blood pressure, automated reading 6.89 7 4 8.9 -0.53 1.4e-01 CLCN6 DCAF16 FES MPI NOC3L SLC25A37 ZNF76
Vascular/heart problems diagnosed by doctor 7.58 6 3 6.7 0.87 5.4e-03 CLCN6 DCAF16 FES MPI PTK2 TEAD3
Cholesterol lowering medication 1.48 1 0 0.0 0.00 1.0e+00 DCAF16
Pain experienced in last month 1.62 1 0 0.0 0.00 1.0e+00 PTK2
Heart attack/myocardial infarction (self-reported) 2.62 2 1 2.2 0.00 1.0e+00 FES TEAD3
Heart disease (siblings) 1.98 1 0 0.0 0.00 1.0e+00 FES
Impedance of whole body 1.17 3 1 2.2 0.00 1.0e+00 NT5C2 PPA2 PTK2
Leg fat mass (left) 2.01 6 2 4.4 0.57 2.4e-01 ADCY5 CLCN6 MPI NT5C2 SLC25A37 ZBTB38
Arm predicted mass (left) 5.86 10 6 13.3 0.73 1.6e-02 ADAM17 ANAPC10 DCAF16 NT5C2 PPA2 RP11-864G5.3 SLC25A37 TEAD3 ZBTB38 ZNF76

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 6 0.172 1.9
GTEx Adipose Visceral Omentum 3 0.147 1.9
GTEx Adrenal Gland 2 0.137 1.8
GTEx Artery Aorta 4 0.134 1.9
GTEx Artery Coronary 1 0.085 1.9
GTEx Artery Tibial 10 0.266 2.0
GTEx Brain Caudate basal ganglia 1 0.109 1.8
GTEx Brain Cerebellar Hemisphere 1 0.067 1.9
GTEx Brain Cerebellum 3 0.151 1.9
GTEx Brain Cortex 1 0.097 1.8
GTEx Brain Frontal Cortex BA9 0 0.000 1.8
GTEx Brain Hippocampus 0 0.000 1.8
GTEx Brain Hypothalamus 1 0.169 1.8
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.8
GTEx Brain Putamen basal ganglia 0 0.000 1.6
GTEx Breast Mammary Tissue 2 0.101 1.8
GTEx Breast Mammary Tissue (Male) 0 0.000 1.8
GTEx Breast Mammary Tissue (Female) 3 0.182 1.8
GTEx Cells EBV-transformed lymphocytes 1 0.070 1.9
GTEx Cells Transformed fibroblasts 5 0.119 1.9
GTEx Colon Sigmoid 1 0.068 1.9
GTEx Colon Transverse 2 0.097 1.8
GTEx Esophagus Gastroesophageal Junction 1 0.069 1.9
GTEx Esophagus Mucosa 5 0.151 1.9
GTEx Esophagus Muscularis 4 0.124 1.9
GTEx Heart Atrial Appendage 3 0.190 1.8
GTEx Heart Left Ventricle 2 0.131 1.8
GTEx Liver 0 0.000 1.8
GTEx Lung 6 0.209 1.9
GTEx Muscle Skeletal 0 0.000 1.8
GTEx Nerve Tibial 9 0.208 1.8
GTEx Ovary 1 0.110 1.9
GTEx Pancreas 1 0.061 1.8
GTEx Pituitary 0 0.000 2.0
GTEx Prostate 1 0.120 1.8
GTEx Skin Not Sun Exposed Suprapubic 4 0.163 1.9
GTEx Skin Sun Exposed Lower leg 6 0.165 1.9
GTEx Small Intestine Terminal Ileum 0 0.000 1.8
GTEx Spleen 3 0.213 1.8
GTEx Stomach 2 0.138 2.0
GTEx Testis 2 0.063 1.8
GTEx Thyroid 3 0.075 1.8
GTEx Uterus 1 0.176 2.0
GTEx Vagina 0 0.000 2.0
GTEx Whole Blood 1 0.050 1.8
METSIM Adipose 6 0.130 1.8
NTR Blood 3 0.125 1.9
ROSMAP Brain Pre-frontal Cortex 2 0.046 1.8
YFS Blood 4 0.087 1.8
CommonMind Brain Pre-frontal Cortex 9 0.167 1.8
The Cancer Genome Atlas Bladder Urothelial Carcinoma 3 0.181 1.8
The Cancer Genome Atlas Breast Invasive Carcinoma 6 0.136 1.8
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 2 0.182 1.9
The Cancer Genome Atlas Colon Adenocarcinoma 3 0.145 1.7
The Cancer Genome Atlas Esophageal Carcinoma 1 0.146 1.7
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.8
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 4 0.147 1.9
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 1 0.024 1.8
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 1 0.049 1.8
The Cancer Genome Atlas Brain Lower Grade Glioma 1 0.023 1.7
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 0 0.000 1.8
The Cancer Genome Atlas Lung Adenocarcinoma 5 0.170 1.8
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 2 0.080 1.7
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 1 0.063 1.7
The Cancer Genome Atlas Pancreatic Adenocarcinoma 2 0.120 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 3 0.226 1.9
The Cancer Genome Atlas Prostate Adenocarcinoma 3 0.065 1.8
The Cancer Genome Atlas Rectum Adenocarcinoma 1 0.145 1.9
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.7
The Cancer Genome Atlas Skin Cutaneous Melanoma 0 0.000 1.8
The Cancer Genome Atlas Stomach Adenocarcinoma 3 0.178 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 2 0.156 1.8
The Cancer Genome Atlas Thyroid Carcinoma 6 0.116 1.8
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.9